The Sydney Morning Herald logo
The Sydney Morning Herald logo

CSL Limited

Advertisement
CSL’s woes extend to the plasma business which generates most of its earnings.

‘Collision with reality’: The $100 billion downfall of an Aussie giant

There is no hiding from the bloody mess at CSL, one of Australia’s global success stories. Can it recover?

  • Colin Kruger

Latest

Under pressure: CSL chairman Brian McNamee.

$88b bloodbath shows Trump is not the only problem for Aussie pharma giant

One of Australia’s biggest companies and most lauded success stories has become an investing disaster of historic proportions.

  • Colin Kruger
Donald Trump signed an executive order to impose 100 per cent tariffs on foreign pharmaceuticals.

Trump imposes 100 per cent tariff on Australian drugs – but with caveats

Australia’s largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances.

  • Michael Koziol
Wall Street had its best day in weeks.

ASX bounces to 50-day high as CBA, AGL soar

Shares in Commonwealth Bank bounced after it revealed a $5.4 billion half-year profit leading the ASX higher.

  • Staff reporter
US Health Secretary Robert F. Kennedy Jr: Having an anti-vaxxer in charge of America’s health system has been one of the factors hitting CSL’s performance.

How RFK, China and leadership woes became a $4b storm for this Australian corporate giant

CSL’s share price has now halved in 18 months, shredding more than $70 billion of shareholder wealth after the latest writedowns and operational struggles. 

  • Colin Kruger
CBA boss Matt Comyn, Helen Lofthouse of the ASX and CSL’s former chief Paul McKenzie.

The good, the bad and the very ugly of profit season

It’s still early in the earnings season, but already we have two chief executive beheadings, while one of the big four banks has posted a stellar result.

  • Elizabeth Knight
Advertisement
Outgoing CSL boss Paul McKenzie.

Boss of $83b giant CSL exits abruptly

Australian pharmaceuticals heavyweight CSL says its chief executive Paul McKenzie is leaving the company with immediate effect.

  • Clancy Yeates
Haemophilia is a disease written into the genes.

This gene therapy costs $5 million a dose. Is it worth the price?

A new wave of gene therapy treatments offer a new lease on life for people with inherited diseases such as haemophilia. But there’s a $5 million problem.

  • Liam Mannix
President Trump and Robert F. Kennedy at a Make America Healthy Again event in May.

How Trump’s antivaxxers helped trigger Aussie giant’s $50b implosion

The deadliest US flu season in decades was expected to immunise CSL’s vaccine business from a growing anti-vaxxer sentiment. That’s not how it has played out.

  • Colin Kruger
Robert F. Kennedy Jr has espoused misinformation around vaccine safety, including a discredited theory that childhood vaccines cause autism.

Aussie giant takes $17b hit as more Americans shun vaccines

A further plunge in US vaccination rates since the appointment of vaccine sceptic Robert F. Kennedy Jr has sparked a fresh earnings blow to biotech giant CSL.

  • Colin Kruger